Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
GSHR
SELLGesher Acquisition Corp. II · Financial Services · United States · $214M · Avg Vol: $48K/d
COMPANY DESCRIPTION
Gesher Acquisition Corp. II is a special purpose acquisition company (SPAC) formed for the purpose of acquiring one or more businesses. It does not currently operate any business and is focused on identifying a target company for a merger, asset acquisition, or similar business combination. The company's value proposition is tied to its management team's ability to source and execute a promising transaction.
FINANCIAL SUMMARY (USD)
| Year | 2024 | 2025 | TTM |
|---|---|---|---|
| Revenue | — | 0 | — |
| EPS | — | 0.20 | 0.24 |
| Shares | 18.5M | 20.5M | — |
| Debt | 12.5K | — | — |
| Equity | 9.8K | 144.5M | — |
| Op CF | — | -0.8M | -1.1M |
| Inv CF | — | -144.2M | — |
| Fin CF | — | 146.1M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Financial Services, ranked by industry match, size, and score similarity. Cross-listings of GSHR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GSHR | Gesher Acquisition Corp. II(you) | $214M | 23 | SELL |
| CCAQ | Collective Acquisition Corp. | $212M | 24 | SELL |
| TDAC | Translational Development Acquisition Corp. | $207M | 22 | SELL |
| DYNC | Dynamix Corporation | $239M | 21 | SELL |
| VNME | Vendome Acquisition Corporation I | $254M | 25 | SELL |
| DMAA | Drugs Made In America Acquisition Corp. | $260M | 25 | SELL |
| ONCH | 1RT Acquisition Corp. | $223M | 19 | STRONG SELL |
| NTWO | Newbury Street II Acquisition Corp | $256M | 26 | SELL |
| TVAI | Thayer Ventures Acquisition Corporation II | $282M | 23 | SELL |
| MACI | Melar Acquisition Corp. I | $236M | 19 | STRONG SELL |
Peer medians: ROE 9.5% · P/E 13.9x · Gross margin 100.0%